This article was originally published here<\/p>\n
Lengthening adalimumab dosing interval in quiescent Crohns disease patients: protocol for the pragmatic randomised non-inferiority LADI study.<\/p>\n
BMJ Open. 2020 May 26;10(5):e035326<\/p>\n
Authors: Smits LJT, Pauwels RWM, Kievit W, de Jong DJ, de Vries AC, Hoentjen F, van der Woude CJ, LADI study group<\/p>\n
AbstractINTRODUCTION: Adalimumab is effective for maintenance of remission in patients with Crohns disease (CD) at a dose of 40mg subcutaneously every 2 weeks. However, adalimumab is associated with (long-term) adverse events and is costly. The aim of this study is to demonstrate non-inferiority and cost-effectiveness of disease activity guided adalimumab interval lengthening compared to standard dosing of every other week (EOW).METHODS AND ANALYSIS: The Lengthening Adalimumab Dosing Interval (LADI) study is a pragmatic, multicentre, open label, randomised controlled non-inferiority trial. Non-inferiority is reached if the difference in cumulative incidence of persistent (>8 weeks) flares does not exceed the non-inferiority margin of 15%. 174CD patients on adalimumab maintenance therapy in long-term (>9 months) clinical and biochemical remission will be included (C-reactive protein (CRP) <10mg\/L, faecal calprotectin (FC) <150g\/g, Harvey-Bradshaw Index (HBI) <5). Patients will be randomised 2:1 into the intervention (adalimumab interval lengthening) or control group (adalimumab EOW). The intervention group will lengthen the adalimumab administration interval to every 3 weeks, and after 24 weeks to every 4 weeks. Clinical and biochemical disease activity will be monitored every 12 weeks by physician global assessment, HBI, CRP and FC. In case of disease flare, dosing will be increased. A flare is defined as two of three of the following criteria; FC>250 g\/g, CRP10 mg\/l, HBI5. Secondary outcomes include cumulative incidence of transient flares, adverse events, predictors for successful dose reduction and cost-effectiveness.ETHICS AND DISSEMINATION: The study is approved by the Medical Ethics Committee Arnhem-Nijmegen, the Netherlands (registration number NL58948.091.16). Results will be published in peer-reviewed journals and presented at international conferences.TRIAL REGISTRATION NUMBERS: EudraCT registry (2016-003321-42); Clinicaltrials.gov registry (NCT03172377); Dutch trial registry (NTRID6417).<\/p>\n
PMID: 32461297 [PubMed in process]<\/p>\n
<\/p>\n
Originally posted here: This article was originally published here Lengthening adalimumab dosing interval in quiescent Crohns disease patients: protocol for the pragmatic randomised non-inferiority LADI study. BMJ Open. Continue reading
\nLengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study. -...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"